{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:24:15Z","timestamp":1792794255391,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060095"],"award-info":[{"award-number":["82060095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460103"],"award-info":[{"award-number":["82460103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Jiangxi Provincial Health Commission","doi-asserted-by":"publisher","award":["2024ZD005"],"award-info":[{"award-number":["2024ZD005"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nanchang University Funding","award":["2023efyA02"],"award-info":[{"award-number":["2023efyA02"]}],"id":[{"id":"https:\/\/ror.org\/042v6xz23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the impact of lipid-lowering drugs (LLDs) and antihypertensive drugs on the risk of aortic diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mendelian randomization was utilized to analyse data from 500\u2009000 participants in the UK Biobank to evaluate the effects of statins, PCSK9 inhibitors (PCSK9i), \u03b2-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies. Real-world pharmacovigilance data from the FAERS (FDA Adverse Event Reporting System) database were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively. Furthermore, the two LLDs reduced the risk of aortic diseases through certain metabolites. Meanwhile, real-world pharmacovigilance reports also indicated a low incidence of aortic diseases with PCSK9i and statin treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LLDs, particularly statins and PCSK9i, significantly protect against aortic diseases, providing a scientific basis for preventing and treating aortic diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf001","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:17:14Z","timestamp":1737616634000},"page":"116-135","source":"Crossref","is-referenced-by-count":7,"title":["Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data"],"prefix":"10.1093","volume":"11","author":[{"given":"Han","family":"Nie","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University , No. 1 Minde Road, Nanchang, Jiangxi 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University , No. 1 Minde Road, Nanchang, Jiangxi 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangxi Provincial Institute of Traditional Chinese Medicine , No. 529 Wenjiao Road, Nanchang, Jiangxi 330007 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3086-6692","authenticated-orcid":false,"given":"Weimin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University , No. 1 Minde Road, Nanchang, Jiangxi 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2025050911514169000_bib1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025050911514169000_bib2","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/cells11142229","article-title":"Extracellular vesicles, inflammation, and cardiovascular disease","volume":"11","author":"Akhmerov","year":"2022","journal-title":"Cells"},{"key":"2025050911514169000_bib3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1089\/omi.2022.0021","article-title":"Multiomics data integration identifies new molecular signatures for abdominal aortic aneurysm and aortic occlusive disease: implications for early diagnosis, prognosis, and therapeutic targets","volume":"26","author":"Kori","year":"2022","journal-title":"OMICS"},{"key":"2025050911514169000_bib4","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"ESC Scientific Document Group. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2025050911514169000_bib5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000502328","article-title":"Association between aortic calcification, cardiovascular events, and mortality in kidney and Pancreas-kidney transplant recipients","volume":"50","author":"Lewis","year":"2019","journal-title":"Am J Nephrol"},{"key":"2025050911514169000_bib6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/iprp.S133088","article-title":"Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?","volume":"8","author":"Mc Namara","year":"2019","journal-title":"Integr Pharm Res Pract"},{"key":"2025050911514169000_bib7","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"Mcevoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025050911514169000_bib8","doi-asserted-by":"publisher","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025050911514169000_bib9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.33963\/KP.a2023.0030","article-title":"PCSK9 inhibitors and reduction in cardiovascular events: current evidence and future perspectives","volume":"81","author":"Nicholls","year":"2023","journal-title":"Kardiol Pol"},{"key":"2025050911514169000_bib10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/1389200219666180816141827","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors, reality or dream in managing patients with cardiovascular disease","volume":"20","author":"Alkhalil","year":"2019","journal-title":"Curr Drug Metab"},{"key":"2025050911514169000_bib11","doi-asserted-by":"publisher","first-page":"Cd011748","DOI":"10.1002\/14651858.CD011748.pub3","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050911514169000_bib12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/ph16050750","article-title":"Effects of lipid-modifying and other drugs on lipoprotein(a) levels-potent clinical implications","volume":"16","author":"Koutsogianni","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025050911514169000_bib13","doi-asserted-by":"publisher","first-page":"e002711","DOI":"10.1161\/circgen.119.002711","article-title":"Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled mendelian randomization investigation","volume":"12","author":"Allara","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"2025050911514169000_bib14","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/jpm11111171","article-title":"Association between lipid levels and risk for different types of aneurysms: a mendelian randomization study","volume":"11","author":"Chen","year":"2021","journal-title":"J Pers Med"},{"key":"2025050911514169000_bib15","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1161\/circulationaha.118.034942","article-title":"Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment","volume":"138","author":"Sliz","year":"2018","journal-title":"Circulation"},{"key":"2025050911514169000_bib16","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/ijms20143458","article-title":"Effect of different classes of antihypertensive drugs on endothelial function and inflammation","volume":"20","author":"Silva","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025050911514169000_bib17","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1161\/hypertensionaha.120.16263","article-title":"Antihypertensive class and cardiovascular outcomes in patients with HIV and hypertension","volume":"77","author":"Rethy","year":"2021","journal-title":"Hypertension"},{"key":"2025050911514169000_bib18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11096-020-00986-6","article-title":"Trends of antihypertensive agents in patients with hypertension and coronary artery disease in a tertiary hospital of China","volume":"42","author":"Zheng","year":"2020","journal-title":"Intl J Clin Pharm"},{"key":"2025050911514169000_bib19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41440-019-0238-2","article-title":"Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study","volume":"42","author":"Ohishi","year":"2019","journal-title":"Hypertens Res"},{"key":"2025050911514169000_bib20","doi-asserted-by":"publisher","first-page":"e030943","DOI":"10.1161\/jaha.123.030943","article-title":"Unraveling potential sex-specific effects of cardiovascular medications on longevity using mendelian randomization","volume":"12","author":"Kwok","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025050911514169000_bib21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ajh.2008.232","article-title":"Unraveling the genetic predisposition for aortic aneurysms: is it time for tailored medicine?","volume":"21","author":"Mukherjee","year":"2008","journal-title":"Am J Hypertens"},{"key":"2025050911514169000_bib22","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2019.11.072","article-title":"Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC Focus seminar","volume":"75","author":"Preiss","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025050911514169000_bib23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025050911514169000_bib24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","article-title":"Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial mendelian randomization study","volume":"7","author":"Cupido","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025050911514169000_bib25","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/circresaha.118.313058","article-title":"Role of resident stem cells in vessel formation and arteriosclerosis","volume":"122","author":"Zhang","year":"2018","journal-title":"Circ Res"},{"key":"2025050911514169000_bib26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1253\/circj.cj-09-0345","article-title":"Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers","volume":"74","author":"Yoshida","year":"2010","journal-title":"Circ J"},{"key":"2025050911514169000_bib27","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1042\/cs20170252","article-title":"ER stress dependent microparticles derived from smooth muscle cells promote endothelial dysfunction during thoracic aortic aneurysm and dissection","volume":"131","author":"Jia","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"2025050911514169000_bib28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2025050911514169000_bib29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.atherosclerosis.2008.08.022","article-title":"The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis","volume":"203","author":"Blum","year":"2009","journal-title":"Atherosclerosis"},{"key":"2025050911514169000_bib30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pharmthera.2014.06.003","article-title":"Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches","volume":"144","author":"Tousoulis","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2025050911514169000_bib31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/path.5421","article-title":"The use of mendelian randomisation to identify causal cancer risk factors: promise and limitations","volume":"250","author":"Gala","year":"2020","journal-title":"J Pathol"},{"key":"2025050911514169000_bib32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.2","article-title":"Mendelian randomization for studying the effects of perturbing drug targets","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"key":"2025050911514169000_bib33","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun"},{"key":"2025050911514169000_bib34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10654-021-00737-5","article-title":"Genetic liability to insomnia in relation to cardiovascular diseases: a Mendelian randomisation study","volume":"36","author":"Yuan","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"2025050911514169000_bib35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40001-022-00825-6","article-title":"The relationship between lipoprotein(a) and risk of cardiovascular disease: a mendelian randomization analysis","volume":"27","author":"Wang","year":"2022","journal-title":"Eur J Med Res"},{"key":"2025050911514169000_bib36","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf001\/61622881\/pvaf001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/2\/116\/61622881\/pvaf001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/2\/116\/61622881\/pvaf001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:51:51Z","timestamp":1746791511000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/2\/116\/7979014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,24]]},"published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf001","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,24]]}}}